In obese people with low growth hormone taking tesamorelin, higher IGF-I levels are linked to better mitochondrial energy efficiency, measured by τPCr.

Scientific Claim

In obese adults with reduced growth hormone secretion treated with tesamorelin, increases in insulin-like growth factor I (IGF-I) levels are associated with improvements in τPCr (R=-0.80, P=0.01), a measure of mitochondrial phosphorylation potential.

Original Statement

“Analyses of subjects treated with tesamorelin only (n = 9 pairs) demonstrated an even stronger statistical association between the increases in IGF-I and improvements in ViPCr (R = 0.71; P = .03) and τPCr (R = −0.80; P = .01) (Supplemental Figure 2, A and B).”

From study:The effects of tesamorelin on phosphocreatine recovery in obese subjects with reduced GH.

Evidence Quality Assessment

Claim Status

appropriately stated

Study Design Support

Design supports claim

Appropriate Language Strength

association

Can only show association/correlation

Assessment Explanation

The study design supports correlational claims. The phrasing 'associated with improvements in τPCr' correctly describes the relationship, noting that a negative R indicates improvement (lower τPCr values).

Evidence from Studies

Supporting (1)

The effects of tesamorelin on phosphocreatine recovery in obese subjects with reduced GH.

Randomized Controlled Trial

Human

2014 Jan

Contradicting (0)

No contradicting evidence found

Source Study

The effects of tesamorelin on phosphocreatine recovery in obese subjects with reduced GH.

Score: 61

DOI: 10.1210/jc.2013-3436

Similar Assertions

When obese people with low growth hormone took a drug called tesamorelin for a year, their muscle energy recovery got better, which means their muscle cells may have become better at making energy.

87%

In obese people with low growth hormone taking tesamorelin, the link between higher IGF-I and better muscle energy recovery is even stronger than in the whole group of participants.

86%

Taking tesamorelin for a year makes IGF-I levels rise much more in obese people with low growth hormone than taking a dummy pill, with a clear difference between the two groups.

86%

Taking tesamorelin for a year makes the hormone IGF-I go up much more in obese people with low growth hormone compared to taking a sugar pill.

86%

In obese people with low growth hormone taking tesamorelin, the link between higher IGF-I and better muscle energy recovery is even stronger than in the whole study group.

83%